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Questions under study: Childhood cancer is
a rare but severe disease. Therefore central regis-
tration of all cases is essential for surveillance and
management. This paper describes the methodol-
ogy and basic results of the Swiss Childhood Can-
cer Registry (SCCR). 
Methods: The SCCR was established in 1976,
originally as a national hospital-based registry of
childhood malignancies. All 9 paediatric oncol-
ogy-haematology clinics in Switzerland provide
baseline and follow-up information on all chil-
dren diagnosed with cancer. These data are regis-
tered centrally and diagnoses are coded according
to the International Classification of Childhood
Cancer. 
Results: From 2001-2005, 887 cases of child-
hood cancer in Swiss residents under the age of
15 years were registered in the SCCR. Of these,
281 (31.7%) were leukaemias, 223 (24.0%) were
CNS tumours, and 116 (13.1%) were lymphomas.
The age-standardised annual incidence per 1 Mil-
lion person-years (age below 15 years; world stan-
dardisation) was 154.0 (95% CI 143.7–164.3; N =
887). The incidence was higher for boys (170.2,
155.0–185.4; N = 501) than for girls (136.9,
123.0-150.8; N = 386). 
Conclusion: The close collaboration between
all paediatric oncologists-haematologists in
Switzerland and a university department allowed
the creation of a national population-based cancer
registry with detailed clinical information. The
SCCR produces cancer type specific incidence
and survival estimates and allows the develop-
ment of nested research projects on childhood
cancer aetiology, management and outcome, both
on a national and on an international level. 
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Introduction 
Childhood cancer is a rare disease with fewer
than 1% of all cancers in industrialised countries
occurring in children younger than 15 years of
age [1]. Tumour types in children are diverse,
many originating from embryonal tissues [2], and
differ from those in adults, where carcinomas pre-
dominate. Albeit its low absolute incidence and
despite dramatic therapeutic improvements,
childhood cancer remains the second most com-
mon cause of death in childhood in Switzerland
[3]. Childhood cancer also accounts for a high
burden of long-term disability caused by the late
effects of the cancer itself or its therapy [4–7]. The
rarity of the disease in combination with its sever-
ity calls for a central registration of all cases in na-
tional and international databases. These allow
time trends in incidence to be monitored, con-
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tributing to the identification of causes and the
study of long-term outcome. 
Specialised childhood cancer registries with
national coverage exist in Germany, the UK and a
few other countries [8–10]. In Switzerland, cancer
registration for patients of all ages is done in 13
cantons covering 58% of the Swiss population
(www.asrt.ch [11]). Children constitute only a
small fraction of cases in these cantonal general
cancer registries and information on clinical pres-
entation, treatment and outcome is limited. For
this reason, the Swiss Paediatric Oncology Group
(SPOG) initiated a nationwide registry of child-
hood malignancies in 1976, the Swiss Childhood
Cancer Registry (SCCR; www.kinderkrebsregis
ter.ch [12]). 
Historical background
During the first four years of its operation
only patients entered into clinical trials were reg-
istered. From 1981 other patients were also in-
cluded. In 1992, the paper-based registry was
transferred to an electronic database and active
long-term follow-up with registration of late ef-
fects was introduced. In 2004, the data centre of
the SCCR was relocated to the Institute of Social
and Preventive Medicine at the University of
Berne. From originally being a hospital-based
registry, the database and methodology were
completely restructured in accordance with inter-
national recommendations [2, 13, 14] and all di-
agnoses were coded according to current classifi-
cation systems [2, 15, 16]. The SCCR was admit-
ted as an associate member of the International
Association of Cancer Registries (IACR) and the
European Network of Cancer Registries (ENCR)
in February 2005.
Purpose and objectives of the SCCR
The SCCR collects data on diagnosis, clinical
presentation, treatment and outcome of all paedi-
atric cancer cases resident in Switzerland, aiming
to: 1) provide national population-based data on
incidence, survival, time trends and regional dif-
ferences of childhood cancer; 2) contribute to the
detection of environmental and genetic risk fac-
tors for childhood cancer and develop preventive
strategies in nested studies and international proj-
ects; 3) assess long-term outcome and late effects
of cancer treatments and help to develop strate-
gies to avoid or mitigate these; 4) provide data for
health care evaluation, planning and quality con-
trol.
For rare tumours the total numbers regis-
tered in Switzerland are low and international col-
laboration is essential. The SCCR therefore partici-
pates in international research projects, for instance
the CEFALO project studying causes of brain 
tumours in children and adolescents (http://www.
research.unibe.ch/abstracts/A_65962086.html).
This paper presents the methodology of the
Swiss Childhood Cancer Registry, selected results
from the past years of operation and a short
overview of current and future developments.
Materials and methods
Case definitions
The SCCR aims to achieve complete registration of
malignant solid tumours, leukaemias and lymphomas (in-
cluding myelodysplastic syndromes), central nervous sys-
tem (CNS) tumours (both malignant and benign) and
Langerhans cell and other histiocytoses among children
under 16 years of age resident in Switzerland. In this
paper, we present data for children less than 15 years of
age. In 2006, diseases for all cases in the database have
been classified according to the International Classifica-
tion of Diseases for Oncology, third edition (ICD-O-3)
[15], and the International Classification of Childhood
Cancer, third edition (ICCC-3) [2].
Population and reporting sources
All children aged less than 16 years who are diag-
nosed or treated in one of the nine paediatric oncology-
haematology units in Switzerland are reported to the
SCCR. These clinics, five of which are linked to a Univer-
sity Hospital, are located in Aarau, Basel, Berne, Geneva,
Lausanne, Locarno, Lucerne, St. Gallen and Zurich. 
A clinical research assistant in each paediatric oncology-
haematology clinic notifies new cases to the data centre in
Berne, using a standard notification form and provides
follow-up data from clinical visits for at least 5 to10 years.
Data collected
The initial patient notification form includes patient
identification data (names, dates of birth, diagnosis, gen-
der, address), information on prior relevant diseases and
diagnostic details (exact diagnosis, localisation, morphol-
ogy, behaviour, staging and metastases). Subsequently de-
tailed data on treatment and outcome (including relapses,
late-effects, second tumours or death) are reported in
yearly intervals. Detailed information on the collected
data is available in the annual reports (www.kinderkrebs
register.ch) [12].
Confidentiality and data protection
The SCCR has been permitted to work with non-
anonymised data by the Swiss expert commission for data
protection in medical research. Data are collected in a
password-protected access database on a stand-alone
computer and analyses are performed with anonymised
data only. Informed consent to collect and transfer data to
the data centre has been obtained from parents and chil-
dren since 2003, the other patients have been informed
and given the option to have their data anonymised (cur-
rently about 4% refuse consent).
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Data quality
Close collaboration between all paediatric oncolo-
gists-haematologists in the SPOG and the small number
of treating institutions enable a timely registration with
very short delays in exchange of data. Incident cases are
reported to the SCCR within two months of diagnosis.
The SCCR maintains close contacts with local clinical
research assistants and clinicians to ensure sustained high
data quality. In 94% of the patients the diagnosis is veri-
fied by a cytological or histological analysis. For the pe-
riod under study the mortality database was not accessed,
and therefore no death certificate only (DCO) cases were
reported. 
At the data centre, details from each patient are
manually checked for completeness, plausibility and con-
sistency. Automatic procedures provided by IACR and
ACCIS (Automated childhood cancer information sys-
tem) have been used annually since 2003. A physician
codes the diagnoses and enters data into the electronic
database. Ambiguities are resolved in collaboration with
the relevant paediatric oncology-haematology clinic. This
includes verifying data for former patients in hospital case
records where necessary. Data are fed back to the clin-
ics through annual reports and on demand through data 
extraction for individual clinics and embedded studies.
Statistical analysis
SCCR data were analysed at the data centre in
Berne, with diagnoses categorised according to the
ICCC-3 [2]. Detailed results are presented for Swiss res-
idents aged <15 years at diagnosis who were diagnosed
with cancer in the years 2001–2005 (N = 887). Incidence
rates were calculated using standard methods (average
annual number of cases per 1 Mio person-years). The de-
nominator data (person-years at risk) used to calculate in-
cidence come from the Swiss Federal Statistical Office
[17]. For the five calendar years considered, person-years
at risk for boys and girls respectively were 185,300 and
175,434 for infants, 763,936 and 721,582 for 1–4 year
olds, 1,043,624 and 988,918 for 5-9 year olds and
1,118,768 and 1,061,246 for 10–14 year olds [17]. The
95% confidence intervals (95%CI) for the incidence
were calculated assuming the counts to be Poisson dis-
tributed [18]. All the statistical analyses were performed
using STATA 8.2 software for Windows (STATA Corpo-
ration, Austin, Texas). 
Results
Overall registry data
Between January 1976 and December 2005 a
total of 5009 cases of childhood cancer had been
registered in the SCCR, 4699 of them in children
aged less than 15 years. Eighty-seven percent of
the children (4363/5009) were Swiss residents at
the time of diagnosis (4085 below 15 years). Of
the 5009 patients, 1204 (24.0%) were reported to
have died (1042/4363 (23.9%) of Swiss residents),
and 882 (17.2%) have been lost to follow-up
(727/4363 (16.7%) of the Swiss residents). 
Childhood cancer between 2001 and 2005
For all subsequent analyses we included only
Swiss residents aged <15 years at diagnosis and di-
agnosed between 1 January 2001 and 31 Decem-
ber 2005 with cancer according to ICCC-3 (table
1). For all malignancies (excluding Langerhans
cell histiocytoses (LCH)) the age-standardised an-
nual incidence per 1 Mio person-years between
2001–2005 was 154.0 (95% CI 143.7–164.3),
higher for boys (170.2, 155.0–185.4) than for girls
(136.9, 123.0–150.8). The incidence in the first 5
years of life (211.2, 191.3–233.3) was nearly twice
as high as in the age group 5 to 14 years (118.0,
108.1–128.8, figure 1). The cumulative risk of de-
veloping cancer within the first 15 years of life was
2240.5/1,000,000 and the median age at diagnosis
was 6.0 years. 
The most common diagnosis in Switzerland
was leukaemia, representing 31.7% of all regis-
tered malignancies in 2001–2005 coded according
to ICCC-3 (table 1). Lymphomas constituted
13.1% of all paediatric malignancies and showed a
marked difference in incidence between genders,
boys being 2.2 times more often affected than
girls. CNS tumours accounted for 24.0% of cases.
While the most common tumour in infancy was
neuroblastoma (32%), leukaemias peaked at age
1–4 years (1–4 year: 43.8%; 5–9 years: 33.3%; 10–
14 years: 24.8%). After age 10 years, embryonal
tumours such as retinoblastoma, nephroblastoma
and hepatoblastoma almost disappeared, whereas
other cancers became more frequent, notably
lymphomas (23.7%) and bone tumours (10.9%).
Solid tumours (not including lymphomas) ac-
counted for 53.2% of cases recorded between
2001 and 2005; 91% of all cases (excluding LCH)
were malignant tumours; the remaining 9% were
non-malignant CNS tumours.
Discussion
This paper describes the evolution of the
Swiss Childhood Cancer Registry from its origin
as a hospital-based case collection into a national
population-based childhood cancer registry with
long-term follow-up. We describe the methodol-
ogy and give incidence data for the last 5-year pe-
riod. Between 2001 and 2005, about 180 new cases
were registered every year in Swiss residents aged 
0 to 14 years, giving an age-standardised incidence
of childhood cancer of 154.0 per 1 Mio person-
years (154/Mio). The relative frequency of various
malignancies and the age-sex distribution are com-
parable to other European countries [19, 20], with
leukaemias comprising about one third and CNS
tumours about one fourth of all tumours.
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Table 1
Frequencies, sex-ratios and number of cases per age-group of childhood malignancies registered in the SCCR (Swiss children below 15 years of age, 
diagnosed between 2001–2005 respectively; diagnoses classified according to ICCC-3*[2]) 
Age groups (in years) Crude Age standardized
incidence incidence
Number %** Girls Boys Sex ratio <1 1–4 5–9 10–14 Median per 1 Mio per 1 Mio
(Boys:Girls) Age per annum per annum
Total (excluding Langerhans 887 100.0 386 501 1.3 100 290 231 266 6.0 146.4 154.0
cell histiocytosis)
Total (including Langerhans 911 396 515 1.3 106 295 240 270 6.0
cell histiocytosis)
I All leukaemias 281 31.7 126 155 1.2 11 127 77 66 5.1 46.4 49.8
Acute lymphoblastic leukaemias 222 79.0 102 120 1.2 6 107 65 44 4.9 36.6 39.8
Acute myeloid leukaemias 40 14.2 15 25 1.7 3 14 7 16 7.1 6.6 6.8
Myelodysplastic syndrome 13 4.6 7 6 0.9 2 2 4 5 8.2 2.1 2.1
Unspecified and other 6 2.1 2 4 2.0 0 4 1 1 3.5 1.0 1.1
specified leukaemias
II Lymphomas 116 13.1 36 80 2.2 5 17 31 63 10.7 19.1 17.9
Hodgkin’s lymphomas 42 36.2 19 23 1.2 0 3 7 32 11.8 6.9 6.0
Non-Hodgkin’s lymphomas 57 49.1 12 45 3.8 2 10 20 25 9.0 9.4 9.0
(except Burkitt lymphoma)
Burkitt lymphoma 12 10.3 3 9 3.0 0 3 4 5 8.6 2.0 1.9
Misc. lymphoreticular neoplasms 4 3.4 1 3 3.0 3 1 0 0 0.9 0.7 0.9
Unspecified lymphomas 1 0.9 1 0 0.0 0 0 0 1 13.6 0.2 0.1
III CNS neoplasms 213 24.0 102 111 1.1 19 61 78 55 6.9 35.2 36.5
Ependymomas and choroids 20 9.4 9 11 1.2 6 10 1 3 2.1 3.3 3.9
plexus tumours
Astrocytomas 68 31.9 33 35 1.1 0 17 33 18 7.6 11.2 11.2
Intracranial and intraspinal 58 27.2 20 38 1.9 11 20 18 9 4.3 9.6 10.6
embryonal tumours
Other gliomas 26 12.2 16 10 0.6 2 8 14 2 5.8 4.3 4.6
Other specified intracranial 40 18.8 23 17 0.7 0 6 11 23 10.6 6.6 6.1
and intraspinal neoplasms
Unspecified intracranial 1 0.5 1 0 0.0 0 0 1 0 9.5 0.2 0.2
and intraspinal neoplasms
IV Neuroblastoma 54 6.0 27 27 1.0 32 18 3 1 0.6 8.7 11.2
Neuroblastoma and 54 100.0 27 27 1.0 32 18 3 1 0.6 8.7 11.2
Ganglioneuroblastoma
V Retinoblastomas 21 2.4 9 12 1.3 12 7 2 0 0.9 3.5 4.4
VI Renal tumours 46 5.2 18 28 1.6 7 28 9 2 2.4 7.6 9.0
Nephroblastomas and other 46 100.0 18 28 1.6 7 28 9 2 2.4 7.6 9.0
non-epithelial renal tumours
VII Liver tumours 9 1.0 0 9 2 4 0 3 1.5 1.5 1.7
Hepatoblastomas 7 77.8 0 7 2 4 0 1 1.2 1.2 1.4
Hepatocellular carcinomas 2 22.2 0 2 0 0 0 2 14.2 0.3 0.3
VIII Malignant bone tumours 52 5.9 26 26 1.0 0 5 18 29 10.2 8.6 7.8
Osteosarcomas 28 53.8 14 14 1.0 0 3 8 17 10.9 4.6 4.2
Chondrosarcomas 0.0
Ewing tumours and related 24 46.2 12 12 1.0 0 2 10 12 9.9 4.0 3.6
sarcomas of bone
IX Soft tissue sarcomas 53 6.0 21 32 1.5 6 17 9 21 6.6 8.7 9.1
Rhabdomyosarcomas 32 60.4 11 21 1.9 3 13 5 11 5.0 5.3 5.6
Fibrosarcomas 4 7.5 2 2 1.0 1 1 1 1 5.2 0.7 0.7
Other specified soft tissue sarcomas 10 18.9 3 7 2.3 0 3 0 7 12.2 1.7 1.6
Unspecified soft tissue sarcomas 7 13.2 5 2 0.4 2 0 3 2 6.6 1.2 1.2
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Incidence of childhood cancer in Switzerland
Our results for incidence of childhood cancer
in Switzerland are comparable to published data
from neighbouring countries. The most compre-
hensive incidence data for all European countries,
based on information from ACCIS have been re-
cently published for the decade 1988–97. For the
time period 1993-1997 overall incidence of child-
hood cancer in Europe was 141/Mio [21]. Inci-
dence was lower (134/Mio) in the British Islands
and higher in the Northern (164/Mio) and South-
ern (162/Mio) European countries. 
More recent data, which can be directly com-
pared to our results have only been published by a
few countries: e.g. the German Childhood Can-
cer Registry (GCCR) [22], which has a compara-
ble methodology to the SCCR, or the United
Kingdom Childhood Cancer Research Group
(UKCCRG) [23]. The total age-standardised in-
cidence of childhood cancer in residents aged 0–
14 years was slightly higher in Switzerland (2001–
2005) than in the UK (1991–2000) and Germany
(2000–2004): SCCR: 154/Mio, 95%CI: 143.7–
164.3; UKCCRG: 139/Mio; GCCR: 147/Mio).
Table 1 (continued).
Age groups (in years) Crude Age standardized
incidence incidence
Number %** Girls Boys Sex ratio <1 1–4 5–9 10–14 Median per 1 Mio per 1 Mio
(Boys:Girls) Age per annum per annum
X Germ cell tumours 25 2.8 14 11 0.8 5 3 3 14 10.3 4.1 4.0
Intracranial and intraspinal germ 7 28.0 2 5 2.5 0 0 3 4 10.3 1.2 1.0
cell tumours
Malignant extra-cranial and 7 28.0 6 1 0.2 4 1 0 2 1.0 1.2 1.3
extra-gonadal tumours
Malignant gonadal germ 10 40.0 5 5 1.0 1 2 0 7 12.6 1.7 1.6
cell tumours
Gonadal carcinomas 1 4.0 1 0 0.0 0 0 0 1 13.9 0.2 0.1
XI Other unspecified carcinomas 16 1.8 7 9 1.3 1 3 1 11 11.4 2.6 2.5
Adrenocortical carcinomas 1 6.3 0 1 0 1 0 0 2.0 0.2 0.2
Thyroid carcinomas 8 50.0 3 5 1.7 0 0 0 8 12.1 1.3 1.1
Malignant melanomas 3 18.8 2 1 0.5 1 0 0 2 11.6 0.5 0.5
Skin carcinomas 1 6.3 0 1 0 1 0 0 2.6 0.2 0.2
Other unspecified carcinomas 3 18.8 2 1 0.5 0 1 1 1 8.9 0.5 0.5
XII Other malignant diseases 1 0.1 0 1 0 0 0 1 12.9 0.2 0.1
Other specified malignant tumours 1 100.0 0 1 0 0 0 1 12.9 0.2 0.1
Langerhans Cell Histiocytosis 24 10 14 1.4 6 5 9 4 5.8 4.0 4.3
*  International Classification of Childhood Cancer – 3rd Edition
**for the calculation of the relative frequency all malignancies coded according to the ICCC-3 were included, excluding Langerhans Cell Histiocytoses
0
50
100
150
200
250
300
350
  0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Age at diagnosis (years)
In
ci
d
en
ce
 p
er
 1
 M
io
 p
er
so
n
-y
ea
rs
Total Boys Girls
Figure 1
Gender and age-spe-
cific incidence rate of
childhood malignan-
cies registered in the
SCCR (Swiss children
diagnosed between
2001–2005).
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For leukaemias (SCCR: 46.4/Mio; UKCCRG:
45.5/Mio: GCCR: 48/Mio), lymphomas (SCCR:
19.1/Mio; UKCCRG: 12.5/Mio: GCCR: 17/Mio),
CNS tumours (SCCR: 35.2/Mio; UKCCRG:
33.5/Mio: GCCR: 32/Mio) and neuroblastoma
(SCCR: 8.7/Mio; UKCCRG: 9.3/Mio: GCCR:
12/Mio) the standardised incidence was similar in
the three countries. Incidence of LHC was com-
parable in Germany (SCCR: 4.3/Mio; 95%CI:
2.6–6.0; GCCR: 6/Mio).
Incidence in the SCCR was also similar to
published data from the Swiss Cantonal Cancer
Registries (ASRT; covering 58% of the Swiss
population) from 2001–2003 [24]: incidence at
age 0–4 years in the SCCR was 237/Mio in males
and 184/Mio in females, compared to 205/Mio
and 165/Mio respectively in the ASRT. For the
age group 5–9 years, the respective incidence for
boys and girls was 128/Mio and 98/Mio in the
SCCR, and 130/Mio and 94/Mio in the ASRT;
and for 10–14 year old boys and girls the inci-
dence was 127/Mio and 117/Mio in the SCCR
and 128/Mio and 130/Mio in the ASRT. 
Strengths and weaknesses of the SCCR 
The evolution of the SCCR from a hospital-
based case collection to a national population-
based cohort study explains most of its weak-
nesses but also its strengths. To begin with the lat-
ter, the SCCR distinguishes itself through a close
collaboration with all paediatric oncologists-
haematologists in Switzerland. Usually, children
with cancer receive treatment in one of only nine
paediatric oncology-haematology centres. Only
these centres, united in the SPOG, can provide
optimal paediatric care, are staffed by specialised
Paediatric Oncologists/Haematologists, are rec-
ognized centres for participation in international
multi-centre clinical studies and can provide ade-
quate insurance coverage. We therefore assume
that the large majority of paediatric cancer cases
in Switzerland are treated in - or have at least
been seen at – one of these clinics. We cannot,
however, exclude the possibility that a small mi-
nority of patients is being missed, such as some
adolescents aged 14–15 years, some children with
benign CNS tumours treated by surgery alone or
cases only diagnosed at autopsy. 
The close collaboration with the clinical cen-
tres also assures timeliness of registration, fast and
straightforward feed-back to the centres, long-
term follow-up data and high quality of the col-
lected information. Data extraction for clinical
studies in the referring centres, individual feed-
back and annual reports enhance cooperation be-
tween the registry and treating physicians. As an
additional aspect of interest the SCCR includes
registration of cases with LCH. LCH is not clas-
sified as a malignant disease according to ICD-O-
3, but has a high incidence of late effects [25] and
a relatively poor survival rate that has increased
from 57% for the period 1954–1968 to 74% for
the period 1985–1998 [26].
A potential problem for the SCCR is com-
pleteness of registration. Until now, cases were
notified mainly through physicians and clinical
research assistants from all paediatric oncology-
haematology units in Switzerland. Deaths were
ascertained via long-term follow-up of patients or
their paediatricians or general practitioners.
Other databases, such as mortality statistics,
pathology reports or archives from other hospi-
tals were not accessed. However, the fact that in-
cidence is similar to published incidence data
from cantonal cancer registries and from the
neighbouring countries France, Germany and
Italy [27–30] suggests that the SCCR includes the
vast majority of cases. Even CNS tumours, a
problematic diagnostic group in many paediatric
cancer registries [29, 31, 32] seem to be well cov-
ered, amounting in 2001–2005 to 24% of all can-
cers. A first study in the 1980s compared com-
pleteness of the SCCR to cantonal general cancer
registries, mortality statistics and hospital
archives. This showed that in 1985-88 the SCCR
included 91% of all leukaemia cases recorded by
the six existing cantonal registries and 80% of
deaths due to childhood leukaemia in the mortal-
ity statistics in 1989 [33]. Based on these consid-
erations, we assume that the SCCR currently cap-
tures at least 90% of all leukaemia cases and solid
malignancies in Switzerland. Currently (2006–
2008) completeness of data on incidence and
mortality in the SCCR is being validated by link-
age with datasets from the Association of Swiss
Cancer Registries and national mortality statis-
tics, and information from hospital archives,
pathology and cytogenetics laboratories. 
Outlook and future developments 
Several ongoing research projects take advan-
tage of the structure and data of the SCCR. A
brief description of the projects is given below.
Long-term outcome and late effects: Im-
proved survival rates from childhood cancer [34,
35] result in a growing population of long-term
survivors. Many of them suffer from late effects of
the cancer itself and its therapy, including late
mortality, somatic health effects and impact on
quality of life and on social integration [6, 7, 36,
37]. It is therefore essential to know how to pre-
dict, prevent and mitigate adverse outcomes
among these young adults. A first large follow-up
study of children and adolescents surviving dis-
ease-free at least 5 years from diagnosis was per-
formed by von der Weid et al between 1990 and
1994. This study showed that in total, 67% of pa-
tients suffered from late effects depending on the
type of tumour, with brain tumour survivors
showing the worst outcome [38]. Even in the
most common cancer, acute lymphoblastic
leukaemia, 17% of the survivors had moderate or
severe somatic or neuropsychological sequelae
[5]. Risk factors for adverse outcomes included
type of tumour [38], cranial irradiation, female
sex, young age at diagnosis [5, 39] and non-inclu-
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sion in a clinical trial [40, 41]. A second long-term
outcome study started in 2006, which includes all
2665 patients diagnosed with a malignant tumour
or CNS tumour at age <16 years before April
2002, who were Swiss residents at the time of di-
agnosis and who survived at least five years. 
Long-term medical care: Another project
evaluates quality of long-term medical care of
cancer survivors in Switzerland. Many late effects
have a better prognosis if diagnosed and treated
early. Regular follow-up by professionals with
specific knowledge is therefore essential to pre-
vent, alleviate and treat these problems [42]. Until
recently, this follow-up was provided mainly by
paediatric oncologists/haematologists, but with
growing numbers of long-term survivors, limited
financial resources and aging of survivors this be-
comes impractical. Experience from abroad shows
that medical care in older survivors is often unsat-
isfactory [43]. A clinical protocol for long-term
follow-up of childhood cancer survivors in
Switzerland has been developed [44] and the on-
going study will show how it has been imple-
mented.
Risk factors for brain tumours: The SCCR
takes part in the international study on risk fac-
tors of CNS tumours in children and adolescents
(CEFALO), which pays special attention to expo-
sure to mobile phones. As a side effect, the study is
likely to improve completeness of registration of
CNS tumours in the SCCR in future because it
establishes a close collaboration with neurosur-
geons, neurologists and oncologists caring for
adolescent patients with CNS tumours [45].
In conclusion, the Swiss Childhood Cancer
Registry evolved from a hospital-based case col-
lection with detailed clinical information to a na-
tional population-based registry with long-term
follow-up, containing a wide range of information
on incidence, survival and late effects of child-
hood cancer. As such, the SCCR has accom-
plished a challenging task because Switzerland is a
country, characterised by a heterogeneity of
health care services and surveillance systems due
to relative independence of individual cantons in
managing their health care policy. This example
might help to show the way for similar undertak-
ings in other paediatric or adult diseases. Cur-
rently, the SCCR database and its nested research
projects provide a valuable resource for national
and international research on childhood cancer.
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